BIIB vs SOLV: fair value comparison
Biogen Inc. and Solventum Corporation · Updated 2026-09-07
BIIB currently screens as fairly valued while SOLV screens as overvalued. Within Healthcare, BIIB currently sits closer to the top of our discount ranking. BIIB carries the stronger quality grade.
| BIIB | SOLV | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $220.83 | $91.69 |
| 12-month range | $151.44–$216.04 | $64.35–$90.95 |
| Sector rank | #86 of 113 Healthcare | #87 of 113 Healthcare |
| Quality grade | B | F |
| Leverage | Low | High |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BIIB fair value analysis · SOLV fair value analysis